These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17924867

  • 1. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.
    Schnell O, Mertes G, Standl E, Acarbose-Insulin Combination Study Group.
    Diabetes Obes Metab; 2007 Nov; 9(6):853-8. PubMed ID: 17924867
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, Cho CG, Sridama W, Writing Group for the Asian Study of Acarbose with Sulfonylureas.
    J Diabetes Complications; 2003 Nov; 17(4):179-85. PubMed ID: 12810240
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S, Le Berre MA, Grangé V.
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [Abstract] [Full Text] [Related]

  • 4. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [Abstract] [Full Text] [Related]

  • 5. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study.
    Hwu CM, Ho LT, Fuh MM, Siu SC, Sutanegara D, Piliang S, Chan JC, Asian Acarbose Study Group.
    Diabetes Res Clin Pract; 2003 May; 60(2):111-8. PubMed ID: 12706319
    [Abstract] [Full Text] [Related]

  • 6. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P, Karrasch J, Scott R, Wilson D, Moses R.
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [Abstract] [Full Text] [Related]

  • 7. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D.
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [Abstract] [Full Text] [Related]

  • 8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 9. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J.
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [Abstract] [Full Text] [Related]

  • 10. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC.
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [Abstract] [Full Text] [Related]

  • 12. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Güvener N, Gedik O.
    Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
    [Abstract] [Full Text] [Related]

  • 13. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
    Mertes G.
    Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [Abstract] [Full Text] [Related]

  • 16. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [Abstract] [Full Text] [Related]

  • 17. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA.
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [Abstract] [Full Text] [Related]

  • 18. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.
    Lindström J, Tuomilehto J, Spengler M.
    Diabet Med; 2000 Jan; 17(1):20-5. PubMed ID: 10691155
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 20. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.